Suppressing β3-integrin triggers a neuropilin-1 dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis

Anti-angiogenic treatments against αvβ3-integrin fail to block tumour growth in the long term, which suggests tumour vascular escape through αvβ3-integrin-independent mechanisms. Here, we show that suppression of β3-integrin leads to the activation of a neuropilin-1 (NRP1) dependent cell migration p...

Full description

Saved in:
Bibliographic Details
Published in:Disease models & mechanisms 2015-01
Main Authors: Ellison, Tim S., Atkinson, Samuel J., Steri, Veronica, Kirkup, Benjamin M., Preedy, Michael E. J., Johnson, Robert T., Ruhrberg, Christiana, Edwards, Dylan R., Schneider, Jochen G., Weilbaecher, Katherine, Robinson, Stephen D.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-angiogenic treatments against αvβ3-integrin fail to block tumour growth in the long term, which suggests tumour vascular escape through αvβ3-integrin-independent mechanisms. Here, we show that suppression of β3-integrin leads to the activation of a neuropilin-1 (NRP1) dependent cell migration pathway in endothelial cells via a mechanism that depends on NRP1's mobilisation away from mature focal adhesions following VEGF-stimulation. The simultaneous genetic targeting of both molecules significantly impairs paxillin-1 activation and focal adhesion remodelling in endothelial cells and therefore inhibits tumour angiogenesis and the growth of already established tumours. These findings provide a firm foundation for testing drugs against these molecules in combination to treat patients with advanced cancers.
ISSN:1754-8403
1754-8411
DOI:10.1242/dmm.019927